Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Basilea partner Asahi Kasei starts phase 2 study of Cresemba in children in Japan
Asahi Kasei Therapeutics has started a multicenter, open‑label phase 2 study in Japan of Cresemba (isavuconazole) in children at risk for invasive mycoses to evaluate safety and pharmacokinetics. Cresemba is already approved for pediatric patients in the US, Canada, Europe and China, but in Japan it is so far approved only for adults. Worldwide in‑market sales of Cresemba amounted to USD 782 million in the April 2025–March 2026 period. » Mere på finanzen.net
Asahi Kasei secures license for Noguchi ADC technology
Asahi Kasei Life Science has acquired licensing rights for an ADC technology developed by the Noguchi Institute that enables control of drug–antibody ratio and binding sites and the conjugation of two different drugs to a single antibody. The partners plan joint research, commercialization and possible sublicensing to biopharma companies and CDMOs such as Bionova Scientific. Asahi Kasei will thereby strengthen its healthcare offering; InvestingPro rates the company as financially very strong and sees upside potential for the share price. » Mere på de.investing.com
Asahi Kasei acquires Aicuris for €780 million
Asahi Kasei has signed a definitive agreement to acquire all shares of Aicuris Anti-infective Cures for around €780 million; closing is expected in the first quarter of fiscal 2026. The acquisition expands Asahi Kasei’s specialty pharma portfolio with three assets, including the already licensed Prevymis, Pritelivir — which is nearing FDA approval with a 2026 target — and AIC468, currently in Phase I with a planned launch in 2030. Asahi Kasei expects the transaction to contribute positively to operating income from fiscal 2028 after amortization, strengthening its position in transplantation, nephrology and severe infectious diseases. » Mere på de.investing.com
Asahi Kasei secures global exclusive license for novel agents against autoimmune diseases
Asahi Kasei Pharma has signed an exclusive global licensing agreement with Alchemedicine for preclinical lead compounds to treat autoimmune diseases, obtaining worldwide rights for research, development, manufacturing and commercialization. The substances were identified using Alchemedicine’s HiSAP platform; the program is independent of a prior 2022 collaboration. The compound AK1960 was recently advanced into a phase‑I study. Asahi Kasei emphasizes its “open innovation” strategy to develop therapy candidates and strengthen its pharma growth target through 2030. » Mere på de.investing.com
Asahi Kasei increases earnings per share and revenue in latest quarter
Asahi Kasei reported earnings per share of 40.03 JPY for the latest quarter, up from 27.65 JPY in the year‑ago quarter. Revenue was 774.90 billion JPY, an increase of 0.78% from 768.92 billion JPY in the year‑ago quarter. The figures come from the quarterly financial conference on February 4, 2026. » Mere på finanzen.net
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 4,84 mia. | 12,33 % |
| Bruttofortjeneste | 1,63 mia. | 16,09 % |
| Nettoresultat | 271,38 mio. | 1,25 % |
| EBITDA | 777,15 mio. | 10,54 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 11,85 mia. € |
Antal aktier | 1,33 mia. |
Højeste/laveste i 52 uger | 10,90 € - 7,13 € |
Udbytteafkast | 2,47 % |
Udbytte TTM | 0,23 € |
Næste udbytte | 0,14 € |
Beta | 0,67 |
P/E (PE Ratio) | 10,78 |
PEG (PEG Ratio) | 0,27 |
K/I (PB Ratio) | 1,00 |
P/S (PS Ratio) | 0,63 |
Virksomhedsprofil
Asahi Kasei Corporation fremstiller, forarbejder og sælger kemiske produkter i Japan og internationalt. Virksomheden er organiseret i tre segmenter: Material, Homes og Health Care. Den leverer kaustisk soda, kemisk gødning, salpetersyre, ammoniak, acrylonitril, methylmethacrylat, styren, adipinsyre, hexamethylendiamin, AH-salt, propionitril, natriumcyanid, acetonitril, methacrylonitril, cyclohexylmethacrylat, cyclohexanol, cyclohexan og cyclohexen; polymerer; kemiske mellemprodukter; additiver; membraner og systemer; clads og anchors; optiske og trykmaterialer; elektroniske materialer; samt separatorer til lithium-ion-batterier og blysyrebatterier. Virksomheden tilbyder cupro-fiber, foringsstof, stretchfiber, spunbond-non-wovens, cupro-non-woven-stof, mikrofiber-ruskind, olie-vand-separator, multifunktionelt non-woven, deodoriserende non-woven, varmepresbart termoplastisk non-woven, støjdæmpende plade, nylonfilamenter, flammehæmmende fiber, honeycomb-stof, cellulose-nanokugler, ecorise, biocradle og bemliese-produkter, samt polymerer; syntetisk gummi; elastomerer; produkter til køkken og husholdning; rengøringsmidler; og emballageprodukter. Derudover leverer virksomheden elektroniske enheder; samt autoklaveret porebeton, fundamentsystemer, isoleringsmaterialer og konstruktionssystemer og -komponenter. Endvidere er den involveret i byggeri af boliger og lejligheder; administration af udlejningsenheder og ejerlejligheder; formidling af brugte boliger; renovering; samt realkreditfinansiering, formueforvaltningstjenester og forsikringsprodukter. Desuden leverer virksomheden lægemidler og diagnostiske reagenser; dialysatorer; terapeutisk aferese; biologiske lægemidler og filtre og udstyr til plasmaderivater samt virusfjernelsesfiltre; leukocytreduktionsfiltre; defibrillatorer, temperaturstyringssystemer og dataløsninger; og UVC LED-produkter. Asahi Kasei Corporation blev grundlagt i 1922 og har hovedkontor i Tokyo, Japan.
| Navn | Asahi Kasei |
| CEO | Koshiro Kudo |
| Hjemsted | Tokyo,
ty Japan |
| Websted | |
| Børsnotering | 04.01.2000 |
| Medarbejdere | 47.895 |
Tickersymboler
| Børs | Symbol |
|---|---|
Japan Exchange Group | 3407.T |
Pnk | AHKSF |
Frankfurt | ASAA.F |
Düsseldorf | ASAA.DU |
München | ASAA.MU |